

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ARGENTUM PHARMACEUTICALS LLC

Petitioner

v.

CIPLA LIMITED

Patent Owner

---

Case No. IPR2017-00807

U.S. Patent No. 8,168,620

---

**CIPLA LTD.'S UPDATED EXHIBIT LIST**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

<i>Cipla's Exhibit #</i>	<i>Description</i>
2001	Warner Carr, M.D. Declaration
2002	Warner Carr, M.D. <i>Curriculum Vitae</i>
2003	Alexander Dominic D'Addio, Ph.D. Declaration
2004	Alexander Dominic D'Addio, Ph.D. <i>Curriculum Vitae</i>
2005	John C. Jarosz Declaration
2006	John C. Jarosz <i>Curriculum Vitae</i>
2007	Hugh David Charles Smyth, Ph.D. Declaration
2008	Hugh David Charles Smyth, Ph.D. <i>Curriculum Vitae</i>
2009	Complaint for Patent Infringement, December 2, 2014, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-UNA (D. Del.)
2010	Complaint for Patent Infringement, September 9, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Perrigo UK Finko Limited Partnership, Perrigo Company and Perrigo Pharmaceuticals Co.</i> , Case No. 1:16-cv-00794-LPS (D. Del.)
2011	Expert Report of Robert P. Schleimer, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2012	Expert Rebuttal Report of Robert P. Schleimer, Ph.D., July 29, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2013	Expert Reply Report of Robert P. Schleimer, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2014	Dr. Maureen Donovan Deposition transcript, October 7, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2015	Expert Report of Maureen D. Donovan, Ph.D., June 30, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)

<b><i>Cipla's Exhibit #</i></b>	<b><i>Description</i></b>
2016	Expert Reply Report of Maureen D. Donovan, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2017	Publicly Filed Proposed Joint Pretrial Order, November 10, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D.I.137) (Redactions in Original)
2018	Bench Trial Transcript, Volume A, December 13, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2019	Bench Trial Transcript, Volume B, December 14, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2020	Bench Trial Transcript, Volume C, December 15, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2021	Bench Trial Transcript, Volume D, December 16, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2022	Plaintiffs' Proposed Findings of Fact, January 10, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 155)
2023	Defendants' Proposed Finding of Facts, January 10, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 156)
2024	Defendants' Opening Post-Trial Brief, January 24, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 158)
2025	Dr. Robert Schleimer Deposition transcript, September 29, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)
2026	Gennaro, A. R. <i>Remington's Pharmaceutical Sciences</i> (17 <sup>th</sup> ed., 1985), Ch. 80: 1455-1477; Ch. 82: 1478-1491; Ch. 84:1492-1517

<i>Cipla's Exhibit #</i>	<i>Description</i>
2027	Accolate Approval Letter and Label, Application Number 20-547/S011, Zeneca Pharmaceuticals
2028	Avomeen Analytical Services Report, June 30, 2016 (PTX0129)
2029	Expert Report of Dr. Matthew J. Herpin and Corresponding Documents (PTX1663)
2030	Expert Report of Dr. Ramprakash Govindarajan and Corresponding Documents (PTX1664)
2031	Duonase Imitator Product Labels (PTX0026)
2032	Allegra-D Approval Letter, Application Number 20786, Approved December 24, 1997, (PTX0126)
2033	Intentionally Left Blank
2034	<i>Physicians' Desk Reference</i> , 54 <sup>th</sup> ed., pp. 1343-1344, 2404-2406, 2781-2783 (2000)
2035	Riordan, John. <i>An Introduction to Combinatorial Analysis</i> (1958), Ch. 1: 1-18
2036	Zyrtec-D FDA Label, Approved August 10, 2001
2037	Argentum Pharmaceuticals, "About," <a href="http://www.argentumpharmaceuticals.com/about/">http://www.argentumpharmaceuticals.com/about/</a> (accessed May 17, 2017)
2038	Khan, M., and Reddy, I. <i>Pharmaceutical and Clinical Calculations</i> (2nd ed., 2000), pp. 149-167 (PTX0194)
2039	Flonase <sup>®</sup> Label 1998, Application Number 20-121/S009, November 1998 (PTX0059)
2040	British Pharmaceutical Codex (1973), "Hypromellose," pp. 232, 307-308 (PTX0193)
2041	Howarth, P. H. "A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis," <i>Allergy</i> , 62: 6-11; 2000 (PTX0337)
2042	Nielsen, Lars P. "Review Article, Intranasal Corticosteroids for Allergic Rhinitis - Superior Relief?" <i>Am. J. Respir Med.</i> , 2(1): 55-65; 2001 (PTX0338)

<b>Cipla's Exhibit #</b>	<b>Description</b>
2043	Shenfield, G. M. "Fixed drug combinations: which ones can be recommended?" <i>Current Therapeutics</i> , 27(11): 15-29; 1986 (DTX-048)
2044	Michael, Y., <i>et al.</i> "Characterisation of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system," <i>International Journal of Pharmaceutics</i> , 221: 165-174; 2001 (PTX0179)
2045	Hampel, F., <i>et al.</i> "Double-blind, Placebo-Controlled Study of Azelastine and Fluticasone in a Single Nasal Spray Delivery Device," <i>Annals of Allergy, Asthma, &amp; Immunology</i> , 105: 168-173; 2010 (PTX0230)
2046	Weiler, J. M., <i>et al.</i> "Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis," <i>Ann. Allergy Asthma Immunol</i> , 79: 327-332; 1997 (PTX0329)
2047	Blaiss, M. "Efficacy, Safety, and Patient Preference of Inhaled Corticosteroids: A Review of Pertinent Published Data," <i>Allergy and Asthma Proc.</i> , 22(6): S5-S10; 2001 (PTX0058)
2048	DataMonitor – "Pipeline and Commercial Insight: Allergic Rhinitis," July 2010 (PTX0396)
2049	2006 Cipla-Meda License Agreement with Quality Agreement (PTX1016)
2050	2011 First Amendment to Cipla-Meda Agreement (PTX0282)
2051	<i>Physicians' Desk Reference</i> , 54 <sup>th</sup> ed., pp. 2783- 2786 (2000)
2052	Leung, D., <i>et al.</i> "The Editors' Choice: MP29-02: A Major Achievement in the treatment of allergic rhinitis," <i>J. Allergy Clin. Immunol.</i> , 129(5): 1216; 2012 (PTX0029)
2053	Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024, GlobalData, September 2015 (PTX0397)
2054	MedPointe Making Medicine Better: Astelin <sup>®</sup> Day Life CyclePlan, November 1, 2002 (PTX1005)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.